IN2014DN00123A - - Google Patents

Download PDF

Info

Publication number
IN2014DN00123A
IN2014DN00123A IN123DEN2014A IN2014DN00123A IN 2014DN00123 A IN2014DN00123 A IN 2014DN00123A IN 123DEN2014 A IN123DEN2014 A IN 123DEN2014A IN 2014DN00123 A IN2014DN00123 A IN 2014DN00123A
Authority
IN
India
Prior art keywords
compounds
mek
inflammation
inhibitors
cancer
Prior art date
Application number
Inventor
Ramulu Poddutoori
Can Wang
Xianglin Zhao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to IN123DEN2014 priority Critical patent/IN2014DN00123A/en
Publication of IN2014DN00123A publication Critical patent/IN2014DN00123A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to compounds (I) and pharmaceutically acceptable salts thereof. The compounds have been demonstrated as inhibitors of MEK and therefore may be useful in the treatment of hyperproliferative diseases like cancer and inflammation.
IN123DEN2014 2011-06-09 2012-06-06 IN2014DN00123A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN123DEN2014 IN2014DN00123A (en) 2011-06-09 2012-06-06

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1634DE2011 2011-06-09
CN201210175145 2012-05-31
PCT/IB2012/052860 WO2012168884A1 (en) 2011-06-09 2012-06-06 Heterocyclic sulfonamide derivatives
IN123DEN2014 IN2014DN00123A (en) 2011-06-09 2012-06-06

Publications (1)

Publication Number Publication Date
IN2014DN00123A true IN2014DN00123A (en) 2015-05-22

Family

ID=46384435

Family Applications (1)

Application Number Title Priority Date Filing Date
IN123DEN2014 IN2014DN00123A (en) 2011-06-09 2012-06-06

Country Status (10)

Country Link
EP (1) EP2718276A1 (en)
JP (1) JP2014517004A (en)
KR (1) KR20140034898A (en)
AU (1) AU2012265844A1 (en)
BR (1) BR112013031201A2 (en)
CA (1) CA2838029A1 (en)
EA (1) EA201391820A1 (en)
IN (1) IN2014DN00123A (en)
MX (1) MX2013014398A (en)
WO (1) WO2012168884A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013094546A1 (en) * 2011-12-19 2013-06-27 住友化学株式会社 Method for producing sulfonate
EP3251673A1 (en) 2012-12-13 2017-12-06 IP Gesellschaft für Management mbH Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
CN104886052B (en) * 2015-06-02 2016-08-31 吉林省八达农药有限公司 A kind of application of cyclopropyl-sulfonylamide
EP3630746A1 (en) * 2017-05-25 2020-04-08 Araxes Pharma LLC Compounds and methods of use thereof for treatment of cancer
WO2019183385A1 (en) * 2018-03-22 2019-09-26 University Of Rochester Mapk/erk inhibition for ovarian and other cancers

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (en) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Ring gap magnet system
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
ATE28864T1 (en) 1982-07-23 1987-08-15 Ici Plc AMIDE DERIVATIVES.
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (en) 1992-04-03 1994-06-21 Ciba Geigy Ag
ATE348110T1 (en) 1992-10-28 2007-01-15 Genentech Inc HVEGF RECEPTOR AS A VEGF ANTAGONIST
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
EP2163546B1 (en) 1995-03-30 2016-06-01 Pfizer Products Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
BR9609617B1 (en) 1995-07-06 2010-07-27 7h-pyrrol [2,3-d] pyrimidine derivatives, and pharmaceutical composition.
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
BR9708640B1 (en) 1996-04-12 2013-06-11 irreversible tyrosine kinase inhibitors and pharmaceutical composition comprising them.
EP0907642B1 (en) 1996-06-24 2005-11-02 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
JP2002513445A (en) 1996-09-06 2002-05-08 オブデュキャット、アクチボラグ Method for anisotropically etching structures in conductive materials
DE19638745C2 (en) 1996-09-11 2001-05-10 Schering Ag Monoclonal antibodies against the extracellular domain of the human VEGF receptor protein (KDR)
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
JP4274583B2 (en) 1996-11-18 2009-06-10 ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング(ゲー・ベー・エフ) Epothilone C, D, E and F, manufacturing and drugs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (en) 1997-02-13 2000-09-01 Novartis Ag PHTHALAZINES, PHARMACEUTICAL PREPARATIONS THAT UNDERSTAND THEM AND THE PROCESS FOR THEIR PREPARATION
CO4940418A1 (en) 1997-07-18 2000-07-24 Novartis Ag MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
NZ506742A (en) 1998-02-25 2003-09-26 Sloan Kettering Inst Cancer Synthesis of desoxyepothilones and hydroxy acid derivative intermediates
ES2342240T3 (en) 1998-08-11 2010-07-02 Novartis Ag ISOQUINOLINE DERIVATIVES WITH ACTIVITY INHIBITED BY ANGIOGENIA.
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (en) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Anthranilic acid amides and use thereof as medicaments
US6303342B1 (en) 1998-11-20 2001-10-16 Kason Biosciences, Inc. Recombinant methods and materials for producing epothilones C and D
ATE300957T1 (en) 1998-12-22 2005-08-15 Genentech Inc ANTAGONISTS OF VASCULAR-ENDOTHELIAL CELL GROWTH FACTORS AND THEIR APPLICATION
CN1221262C (en) 1999-03-30 2005-10-05 诺瓦提斯公司 Phthalazine derivatives for treating inflammatory diseases
PE20020354A1 (en) 2000-09-01 2002-06-12 Novartis Ag HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
JP2006083137A (en) * 2004-09-17 2006-03-30 Sankyo Co Ltd Immunosuppressive agent
EA200900959A1 (en) * 2007-01-19 2010-02-26 Арди Байосайенсиз, Инк. MEK INHIBITORS
JP5479337B2 (en) * 2007-07-30 2014-04-23 アルディア バイオサイエンス,インク. Combination of MEK inhibitor and RAF kinase inhibitor and use thereof
CA2717529A1 (en) * 2008-03-11 2009-09-17 Cellzome Limited Sulfonamides as zap-70 inhibitors
US8841462B2 (en) * 2008-07-01 2014-09-23 Robert A. Heald Bicyclic heterocycles as MEK kinase inhibitors
CA2761108A1 (en) * 2009-04-21 2010-10-28 Novartis Ag Heterocyclic compounds as mek inhibitors
CN102134218A (en) * 2009-06-15 2011-07-27 凯美隆(北京)药业技术有限公司 6-aryl amino pyridone sulfamide and 6-aryl amino pymetrozine sulfamide methyl ethyl ketone (MEK) inihibitor
AU2010317167B2 (en) * 2009-11-04 2012-11-29 Novartis Ag Heterocyclic sulfonamide derivatives useful as MEK inhibitors
EP2509964B1 (en) * 2009-12-08 2014-04-30 Novartis AG Heterocyclic sulfonamide derivatives

Also Published As

Publication number Publication date
MX2013014398A (en) 2014-03-21
CA2838029A1 (en) 2012-12-13
WO2012168884A1 (en) 2012-12-13
JP2014517004A (en) 2014-07-17
AU2012265844A1 (en) 2013-05-02
EP2718276A1 (en) 2014-04-16
EA201391820A1 (en) 2014-12-30
KR20140034898A (en) 2014-03-20
BR112013031201A2 (en) 2017-01-31

Similar Documents

Publication Publication Date Title
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
AU2012214029A8 (en) Rorgammat inhibitors
IN2015DN01156A (en)
PH12014501561A1 (en) Therapeutically active compounds and their methods of use
IN2014KN00769A (en)
CR20200479A (en) Therapeutically active compounds and their methods of use
MX2011011083A (en) Heterocyclic compounds as mek inhibitors.
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
IN2014MN00948A (en)
MX349159B (en) Deuterated derivatives of ivacaftor.
EP2750694B8 (en) Methods and compositions relating to p62 for the treatment and prophylaxis of cancer
IN2014MN00987A (en)
IN2015DN01119A (en)
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
MX348726B (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation.
MX353762B (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation.
WO2015003355A3 (en) Therapeutically active compounds and their methods of use
MX2013012977A (en) Thiazole derivatives.
MX2014003376A (en) Benzoic acid derivatives as eif4e inhibitors.
EA032271B9 (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
IN2014DN00123A (en)
TN2012000242A1 (en) Heterocyclic sulfonamide derivatives
MX2015007945A (en) Uses and methods for the treatment of liver diseases or conditions.
IN2014DN03010A (en)
MX348147B (en) Bisarylsulfonamides useful in the treatment of inflammation and cancer.